Physician Payments Sunshine Act Reintroduced for 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Physician Payments Sunshine Act Reintroduced for 2009


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (Jan. 22)—Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) introduced S. 301, known as the Physician Payments Sunshine Act of 2009 to the 111th Congress. The legislation requires drug, device, and medical-supply manufacturers that receive payments through Medicare, Medicaid, or the State Children's Health Insurance Program (SCHIP) to disclose to the US Department of Health and Human Services (HHS) any things of value they give to doctors. Items include payments, gifts, travel compensation, honoraria, and funding for continuing education and research. Companies would be required to report these items beginning Mar. 31, 2011.

The bill also requires HHS to establish procedures for companies to submit the required information and procedures for HHS to make this information available online by Sept. 20, 2011.

The bill amends title XI of the Social Security Act “to provide transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals.” The bill is similar to S. 2029,  which is the 2008 version that was introduced to the 110th Congress but never acted upon. The 2009 legislation clarifies the preemption provisions that were questioned in the previous version. The new bill specifies that states have the authority to collect additional information from companies as long as the information is not specifically covered by federal law.

The bill has been referred to the Senate Committee on Finance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here